Market Overview

ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Share:

SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities.

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "As COVID-19 restrictions gradually lift in Singapore we expect to resume recruitment into our multiple ascending dose (MAD) study of ASLAN004 in early August. With the continuing impact of COVID-19 causing some delays in patient recruitment, we plan to share further data from the trial during the fourth quarter of 2020. We have been proactive in preparing to open new study sites in Australia and the US to ensure we can accelerate recruitment, as well as support our planned global Phase 2b study in atopic dermatitis in 2021."

Second quarter 2020 and recent business highlights

Clinical development

ASLAN004

  • Recruitment paused into randomised, double-blind, placebo-controlled MAD study of ASLAN004 in moderate to severe atopic dermatitis (AD) in April 2020 in response to government restrictions in Singapore to contain the spread of COVID-19.
  • To accelerate recruitment, ASLAN has identified several clinical sites in Australia and the US that could join the ongoing MAD study in the third quarter.
  • Clinical trial application submitted and regulatory process underway in Australia to initiate recruitment of patients into the ongoing MAD study.
  • Preparations underway to file Investigational New Drug application to the US Food and Drug Administration later this month.

Varlitinib

  • Two abstracts on varlitinib presented at the American Society of Clinical Oncology (ASCO) virtual congress.
                 

Anticipated upcoming milestones for ASLAN004

  • Interim, unblinded data from the 3 dose cohorts (up to 24 patients) expected in 4Q 2020, and initiation of the expansion cohort (an additional 18 patients).
  • Completion of MAD clinical trial in moderate-to-severe AD patients in 1H 2021.
  • Initiation of Phase 2b study of ASLAN004 for AD in 2021.

Second quarter 2020 financial highlights

  • Cash used in operations for the second quarter of 2020 was US$3.0 million compared to US$6.5 million in the same period in 2019.
  • Research and development expenses were US$1.9 million in the second quarter of 2020 compared to US$5.3 million in the second quarter of 2019. The decrease was driven by the completion of clinical studies related to varlitinib and lower manufacturing expenses.
  • General and administrative expenses were US$1.8 million in the second quarter of 2020 compared to US$1.9 million in the second quarter of 2019. The decrease was primarily due to lower headcount and staffing costs.
  • Net loss for the second quarter of 2020 was US$4.0 million compared to a net loss of US$7.9 million for the second quarter of 2019.
  • Cash, cash equivalents and short-term investments totaled US$13.8 million as of 30 June 2020 compared to US$22.2 million as of 31 December 2019. Weighted average shares outstanding for the second quarter of 2020 was 190.0 million compared to 160.2 million for the second quarter of 2019. One American Depositary Share is the equivalent of five ordinary shares.
 
 
ASLAN Pharmaceuticals Limited
CONSOLIDATED BALANCE SHEET1
(in US dollars)
         
    December 31, 2019   June 30, 2020
(audited) (unaudited)
ASSETS                
                 
CURRENT ASSETS                
Cash and cash equivalents   $ 22,203,031     $ 13,827,444  
Prepayments     68,923       295,203  
                 
   Total current assets     22,271,954       14,122,647  
                 
NON-CURRENT ASSETS                
Financial assets at fair value through profit or loss     68,256       59,002  
Financial assets at fair value through other comprehensive income     132,160       57,829  
Property, plant and equipment     38,333       22,203  
Right-of-use assets     727,866       594,952  
Intangible assets     2,845       888  
Refundable deposits     108,076       108,076  
                 
   Total non-current assets     1,077,536       842,950  
                 
TOTAL ASSETS   $ 23,349,490     $ 14,965,597  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables   $ 1,871,843     $ 1,410,546  
Other payables     3,246,842       2,684,612  
Lease Liabilities - current     264,543       274,077  
                 
   Total current liabilities     5,383,228       4,369,235  
                 
NON-CURRENT LIABILITIES                
Financial liabilities at fair value through profit or loss     262,350       262,350  
Long-term borrowings     17,065,305       17,120,010  
Long-term borrowing from related parties     566,176       607,661  
Lease Liabilities - non-current     490,835       351,934  
Other non-current liabilities     184,870       253,596  
                 
   Total non-current liabilities     18,569,536       18,595,551  
                 
Total liabilities     23,952,764       22,964,786  
                 
EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY                
Ordinary shares     61,366,844       61,366,844  
Capital surplus     116,495,710       116,495,710  
Accumulated deficits     (179,484,825 )     (186,490,714 )
Other reserves     (55,084 )     (129,415 )
                 
   Total equity attributable to stockholders of the Company     (1,677,355 )     (8,757,575 )
                 
NON-CONTROLLING INTERESTS     1,074,081       758,386  
                 
Total equity     (603,274 )     (7,999,189 )
                 
TOTAL LIABILITIES AND EQUITY   $ 23,349,490     $ 14,965,597  
                 


ASLAN Pharmaceuticals Limited
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)1
(in US dollars, unaudited)
 
    For the Three Months Ended June 30
    For the Six Months Ended June 30
 
      2019       2020       2019       2020  
NET REVENUE   $ -     $ -     $ 3,000,000     $ -  
                                 
COST OF REVENUE     -       -       (425,000 )     -  
                                 
GROSS PROFIT     -       -       2,575,000       -  
                                 
OPERATING EXPENSES                                
General and administrative expenses     (1,885,444 )     (1,790,880 )     (4,141,805 )     (2,788,423 )
Research and development expenses     (5,288,633 )     (1,892,559 )     (9,738,165 )     (4,247,175 )
Total operating expenses     (7,174,077 )     (3,683,439 )     (13,879,970 )     (7,035,598 )
                                 
LOSS FROM OPERATIONS     (7,174,077 )     (3,683,439 )     (11,304,970 )     (7,035,598 )
                                 
NON-OPERATING INCOME AND EXPENSES                                
Interest income     75,187       114       144,211       216  
Other gains and losses     (157,789 )     (65,816 )     (237,344 )     391,435  
Finance costs     (202,206 )     (338,612 )     (401,906 )     (677,637 )
Total non-operating income and expenses     (284,808 )     (404,314 )     (495,039 )     (285,986 )
                                 
LOSS BEFORE INCOME TAX     (7,458,885 )     (4,087,753 )     (11,800,009 )     (7,321,584 )
                                 
INCOME TAX EXPENSE     (472,082 )     -       (475,000 )     -  
                                 
NET LOSS FOR THE PERIOD     (7,930,967 )     (4,087,753 )     (12,275,009 )     (7,321,584 )
                                 
OTHER COMPREHENSIVE LOSS                                
Items that will not be reclassified subsequently to profit or loss:                                
Unrealized loss on investments in equity instruments at fair value through other comprehensive income     -       (39,324 )     -       (74,331 )
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD   $ (7,930,967 )   $ (4,127,077 )   $ (12,275,009 )   $ (7,395,915 )
                                 
NET LOSS ATTRIBUTABLE TO:                                
Stockholders of the Company   $ (7,930,967 )   $ (3,959,184 )   $ (12,275,009 )   $ (7,005,889 )
Non-controlling interests     -       (128,569 )     -       (315,695 )
    $ (7,930,967 )   $ (4,087,753 )   $ (12,275,009 )   $ (7,321,584 )
                                 
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO:                                
Stockholders of the Company   $ (7,930,967 )   $ (3,998,508 )   $ (12,275,009 )   $ (7,080,220 )
Non-controlling interests     -       (128,569 )     -       (315,695 )
    $ (7,930,967 )   $ (4,127,077 )   $ (12,275,009 )   $ (7,395,915 )
                                 
LOSS PER SHARE                                
Basic and diluted   $ (0.05 )   $ (0.02 )   $ (0.08 )   $ (0.04 )
Weighed-avg. shares outstanding (in thousands)     160,249       189,955       160,249       189,955  
                                 
1 Financial Statements in US dollars are prepared by the company and are unaudited by certified public accountant as of 30 Jun 2020.


Media and IR contacts  
   
Emma Thompson
Spurwing Communications
Tel: +65 6751 2021
Email: ASLAN@spurwingcomms.com
Robert Uhl
Westwicke Partners
Tel: +1 858 356 5932
Email: robert.uhl@westwicke.com
   

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN's partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.

Forward looking statements

This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's prospectus dated May 8, 2018 filed with the US Securities and Exchange Commission on such date and its 20-F filed April 16, 2020.  

All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com